Unpacking the Role of Cannabis in Oncology as Reclassification of the Drug Pends

Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.

Related Keywords

Pennsylvania ,United States ,Philadelphia ,Dronabinol Marinol ,Brooke Worster ,Business Master Program ,Senate Majority Leader Chuck Schumer ,Jefferson Health ,Human Services ,Centers For Disease ,Institute Of Emerging Health Professions ,Us Department Of Health ,Drug Enforcement Administration ,Supportive Oncology At Jefferson Health ,Disease Control ,Controlled Substances ,Supportive Oncology ,Cannabis Medicine ,Business Master ,Emerging Health Professions ,Accessed March ,Cannabis ,Reclassification Of Cannabis ,D ,Us ,Naacp ,Expectant Marijuana Reclassification Froma Schedulei Toa Schedule Iii Drug ,Medical Cannabis ,Controlled Substances Act ,